Skip to main content
. 2016 Jun 16;7:11798. doi: 10.1038/ncomms11798

Figure 7. Suspension survival determines tumorigenicity and corresponds to clinical tumour staging and survival.

Figure 7

(a) Tumorigenicity of bulk cancer cells expressing DN PP2A and S727E point-mutated STAT3 with or without shRNA against Col17a1 or TICs overexpressing WT PP2A, S727A point-mutated STAT3 and shRNA against Col17a1. (b) The expression of pS727STAT3 and Col XVII in primary colorectal tumours was detected by immunohistochemical staining of tissue array slides. Top, representative pictures of positive staining of colorectal tumour tissues (different stages) are shown. Bottom, quantification and the correlation between protein expression and tumour stages was subsequently determined. The results are expressed as percentage of diaminobenzidine (DAB)-positive cells, and every single plot represents a patient. The median is shown as a single black line. (c) The survival curves of 150 colorectal cancer patients with or without upregulated pS727STAT3 and Col XVII expression (calculated using the Kaplan–Meier method). The expression of pS727STAT3≥40% or Col XVII≥50% was regarded as positive. Asterisks indicate significant differences (*P<0.05, **P<0.01 versus CTR) determined by Fisher's exact test (a), one-way ANOVA (b) and log-rank test (c). Scale bar, 50 μm.